News
On the horizon: Asciminib, a new drug for treating r/r CML
- Author:
- Alexander M. Castellino, PhD
“Although we have many excellent therapies for CML, having a new medication that targets BCR-ABL in a novel way is still welcome to help us better...
News
Five-minute SC injection of daratumumab in RRMM
- Author:
- Alexander M. Castellino, PhD
“The appeal of subcutaneous daratumumab is the 5 minutes it needs for administering, cutting down considerable on ‘chair/clinic’ time.”
News
In MDS, transplant ups survival in elderly and may be reimbursed
- Author:
- Alexander M. Castellino, PhD
In patients with a median age of 66 years who had received a donor transplant, the overall survival at 3 years...
News
‘Momentous’ data for first-line combo in liver cancer
- Author:
- Alexander M. Castellino, PhD
Atezolizumab plus bevacizumab improved survival, when compared with sorafenib, in patients with unresectable...
News
Oral azacitidine: First maintenance therapy for AML
- Author:
- Alexander M. Castellino, PhD
ORLANDO – Investigators called CC-486, an oral formulation of azacitidine, a “new therapeutic standard” for patients with acute myeloid leukemia...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_220.jpg)
Global burden of hematologic malignancies
- Author:
- Alexander M. Castellino, PhD
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blobel-gerd-CHOP-220.jpg)
Kinase may be therapeutic target for hemoglobinopathies
- Author:
- Alexander M. Castellino, PhD
A kinase called heme-regulated inhibitor (HRI) could be a therapeutic target for sickle cell disease (SCD) and some forms of β-thalassemia,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/prescriptions_Credit_CDC_230.jpg)
Breakthrough drugs approved with less stringent criteria
- Author:
- Alexander M. Castellino, PhD
Clinical trials supporting the approval of drugs with breakthrough therapy designation1 do not meet the same standards as trials for non-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/PET_scan_body_Credit_Jens_Langner_230.jpg)
PET-guided treatment didn’t improve outcomes
- Author:
- Alexander M. Castellino, PhD
In the PETAL trial, treatment intensification based on results of an interim positron emission tomography (PET) scan did not improve survival...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/antibiotic-seth-dixon-stjude-180.jpg)
Mutations linked to higher risk of SNs in CCSs
- Author:
- Alexander M. Castellino, PhD
New research has shown that childhood cancer survivors (CCSs) with certain germline mutations have higher relative rates (RRs) of secondary...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/multiple_myeloma_bone_marrow_aspirate_showing_230.jpg)
Inhibitor could be repurposed for MM
- Author:
- Alexander M. Castellino, PhD
Tofacitinib, a pan-JAK inhibitor approved to treat rheumatoid arthritis, may advance as a potential treatment for multiple myeloma (MM) based on...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg)
Transplant strategy not viable for aggressive B-NHL
- Author:
- Alexander M. Castellino, PhD
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
Group updates guidelines on CLL
- Author:
- Alexander M. Castellino, PhD
Recent advances in chronic lymphocytic leukemia (CLL) have prompted an update to the 2008 International Workshop in Chronic Lymphocytic Leukemia (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/18_ASCO_SM_poster-session.jpg)
Ivosidenib active in R/R IDH1-mutated AML patients
- Author:
- Alexander M. Castellino, PhD
CHICAGO—The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/18ASCO_ZBH_general-view.jpg)
Ibrutinib and venetoclax combo promising in frontline CLL
- Author:
- Alexander M. Castellino, PhD
CHICAGO—Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic...